Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
COSTS AND EXPENSES:    
Research and development $ 81,876 $ 68,838
General and administrative 30,215 23,474
  112,091 92,312
Operating loss (112,091) (92,312)
Interest income 1,873 25
Net loss (110,218) (92,287)
Preferred stock deemed dividend 6,659
Net loss available to common stockholders $ (116,877) $ (92,287)
Net loss per common share, basic $ (3.27) $ (8.10)
Net loss per common share, diluted $ (3.27) $ (8.10)
Weighted average common shares outstanding, basic 35,739,057 11,387,308
Weighted average common shares outstanding, diluted 35,739,057 11,387,308